monoclonal antibody

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin

3 Comments / This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long …

TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin Read More »

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection. Click …

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin Read More »

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow to playDownload TWiV 831 (20 MB .mp3, …

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin Read More »

TWiV 828: COVID-19 clinical update #88 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death. Show notes at microbe.tv/twiv

Dynamics of SARS-CoV-2 Vaccine-Induced Antibody Immunity

2 Comments / Basic virology, Gertrud Rey / By Gertrud U. Rey

It is slowly becoming clear that the immunity induced by SARS-CoV-2 vaccination is of overall better quality than that induced by COVID-19.

Camelids for COVID

2 Comments / Basic virology, Information / By Vincent Racaniello

Human monoclonal antibodies that block infection with SARS-CoV-2 are being used to treat COVID-19 patients, but an alternative, antibodies produced in camelids (alpacas and llamas) might have advantages. Camelid monoclonal antibodies can be more cheaply produced in mass quantities in bacteria, and protein engineering can be quickly used to produce a better therapeutic product. Human …

Camelids for COVID Read More »

Start typing and press enter to search